VCYT Q1 2021 Earnings — Veracyte, Inc. Revenue & Financial Results | Market Cap Arena

VCYTVeracyte, Inc.

$3B

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$37M+17.9% YoY

Gross Profit

$24M66.2% margin

Operating Income

-$45M-123.7% margin

Net Income

-$42M-114.1% margin

EPS (Diluted)

$-0.66

QoQ Revenue Growth

+6.3%

Cash Flow

Operating Cash Flow

-$41M

Free Cash Flow

-$42M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$1.0B

Total Liabilities

$51M

Stockholders' Equity

$974M

Cash & Equivalents

$324M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$37M	$31M	+17.9%
Gross Profit	$24M	$19M	+28.7%
Operating Income	-$45M	-$12M	-272.3%
Net Income	-$42M	-$12M	-257.4%

Revenue Segments

Product

$3M84%

Biopharmaceutical

$566,00016%